PMID- 15363304
OWN - NLM
STAT- MEDLINE
DCOM- 20061031
LR  - 20151119
IS  - 0529-5815 (Print)
IS  - 0529-5815 (Linking)
VI  - 42
IP  - 13
DP  - 2004 Jul 7
TI  - [The function of the level of serum carcinoembryonic antigen on early recurrence 
      of non-small cell lung cancer].
PG  - 817-9
AB  - OBJECTIVE: To explore clinical and pathological factors correlating with early 
      recurrence of resected non small cell lung cancer (NSCLC), and to further 
      understand the function of serum carcinoembryonic antigen (CEA) on NSCLC. 
      METHODS: 93 patients of NSCLC were selected. All of them received resection and 
      were followed up for more than one year. The first time of recurrence was 
      recorded. Logistic univariate and multivariable analysis were used to find the 
      factors that affect the early recurrence of NSLSC, including age, sex, serum CEA 
      level, tumor size, tumor location, tumor differentiation, histological type and 
      clinical staging, and the ability of factors predicting the recurrence were 
      compared by receiver operating characteristic (ROC) curve. RESULTS: Of all the 
      clinical and pathological factors that are correlated with early recurrence of 
      NSCLC, the serum carcinoembryonic antigen (CEA) value, clinical staging, and 
      tumor difference are of statistical significance. The preoperative serum CEA 
      value is the most valuable factor to predict early recurrence of NSCLC (ROC area: 
      0.843, 95% CI: 0.723 approximately 0.963, P = 0.000). When preoperative serum CEA 
      value > 10 micro g/L, patients of NSCLC will have an early recurrence rate of 
      88%; and when preoperative serum CEA value </= 10 micro g/L, the probability of 
      no early recurrence is 92%. CONCLUSION: For the patients with respectable NSCLC, 
      it is very important to know the precise clinical stage and pathological 
      difference, and so is the preoperative serum CEA value. When preoperative serum 
      CEA value > 10 micro g/L, even if the lesion is of early stage and well 
      differenced, the general situation of patients should be carefully examined for 
      the prompt and accurate treatment to them and close follow up is needed to treat 
      these patients.
FAU - Zhang, Zhen-fa
AU  - Zhang ZF
AD  - Thoracic Department of the First Affiliated Hospital of China Medical University, 
      Shenyang 110001, China.
FAU - Ma, Jian-qun
AU  - Ma JQ
FAU - Sun, Nan
AU  - Sun N
FAU - Zhang, Lin
AU  - Zhang L
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Wai Ke Za Zhi
JT  - Zhonghua wai ke za zhi [Chinese journal of surgery]
JID - 0153611
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Carcinoembryonic Antigen)
SB  - IM
MH  - Biomarkers, Tumor/*blood
MH  - Carcinoembryonic Antigen/*blood
MH  - Carcinoma, Non-Small-Cell Lung/*blood/pathology/surgery
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Lung Neoplasms/*blood/pathology/surgery
MH  - Male
MH  - Neoplasm Recurrence, Local/*diagnosis
MH  - ROC Curve
MH  - Risk Factors
EDAT- 2004/09/15 05:00
MHDA- 2006/11/01 09:00
CRDT- 2004/09/15 05:00
PHST- 2004/09/15 05:00 [pubmed]
PHST- 2006/11/01 09:00 [medline]
PHST- 2004/09/15 05:00 [entrez]
PST - ppublish
SO  - Zhonghua Wai Ke Za Zhi. 2004 Jul 7;42(13):817-9.